

REMARKS

Claim 38 is currently pending in the application. In the Office Action issued October 4, 2006, the Examiner indicated that claim 38 was allowable. The specification is amended herein to identify nucleotide and/or amino acid sequences with corresponding SEQ ID NOs in order to fully comply with 37 C.F.R. § 1.821. No new matter is added by these amendments. Therefore, pursuant to the following remarks, Applicant respectfully requests entry of these amendments, reconsideration of the application and allowance of claim 38 to issue.

Objection to the Specification

The Office Action states that the specification contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821 (a)(1) and (a)(2) and which are not specifically identified by SEQ ID NOs. According to the Office Action, pages 13-14, 20-21, 47, 68, 76, 93-97, 112, 115, 124 and 126 of the specification contain numerous sequences which are allegedly not identified by SEQ ID NOs. Further, it is allegedly unclear whether these sequences are present in the paper copy and CRF of the sequence listing filed in this application on 7/26/00. The Examiner has stated that if the sequences are present in the paper and CRF listings, applicant may fully comply with 37 C.F.R. § 1.821 by amending the specification to include the proper SEQ ID NO for each recitation of a sequence. If the sequences are not present in the filed paper and CRF listings, then new paper and CRF sequence listings are required as set forth in the Notice to Comply.

As stated above, the specification is amended herein on pages 13-14, 20-21, 47, 68, 76, 93-97, 112, 115, 124 and 126 to properly identify amino acid and nucleic acid sequences with SEQ ID NOs. The sequences identified on the above-mentioned pages are present in the paper copy and CRF of the sequence listing as filed on July 26, 2000. Therefore, it is not necessary to provide a new paper copy and CRF of the sequence listing. Applicant believes that the application is now in compliance with 37 C.F.R. § 1.821 and respectfully requests withdrawal of this objection.

Pursuant to the above amendments and remarks, reconsideration and allowance of the pending application is believed to be warranted. The Examiner is invited and encouraged to directly contact the undersigned if such contact may enhance the efficient prosecution of this application to issue.




ATTORNEY DOCKET NO. 14162.0001U1
U.S. APPLICATION SERIAL NO. 09/300,959



A Credit Card Payment Form PTO-2038 authorizing payment in the amount of \$60.00 representing the fee under 37 C.F.R. § 1.17(a)(1) for a small entity is enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.


Lizette M. Fernandez, Ph.D.
Registration No. 46,694

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

<u>CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8</u>	
I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.	
 Lizette M. Fernandez	 Date